Multiplex imaging and analysis using the Enable Cloud Platform to predict TNF inhibitor response in ulcerative colitis patients

Case study
April 1, 2023
Ulcerative colitis (UC) is a chronic-relapsing inflammatory bowel disease (IBD). Patients with UC have a 1.5 times higher risk for colorectal cancer compared to healthy individuals. TNF inhibitors such as infliximab and adalimumab are frontline targeted therapies for UC but 13-40% UC patients are non-responsive to TNFi therapy and up to 46% show loss of resistance. Since these drugs are immunosuppressive, they can lead to opportunistic infections, driving up the cost following UC treatment, especially in non-responders. In order to implement individualized therapy to patients effectively, it is critical to understand the differences between individual patients that could affect responses to TNF therapy.

Please complete the form to download this resource

Thanks! Your resource is now ready. Click the button below to download.
Download the PDF
Thank you for contacting us! 
We’ll get back to you shortly.